Pathogenesis Section Bibliography

• Bouchard C, Lacroix C, Plante V, et al. Clinopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52:498-503.
• Dalakas MC. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol. 1999;12:403-409.
• Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol. 1980;37:637-640.
• Dalakas MC, Houff SA, Engel WK., Madden DL, Sever JL. CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology 1980;30:864-867.
• Dyck PJ, Prineas J, Pollard J. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al, Eds. In: Peripheral neuropathy. Philadelphia: WB Saunders, 1993:1498-1517.
• Gold R, Archelos JJ, Hartung HP. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol. 1999;9:343-360.
• Hartung HP, Reiners K, Schmidt B, et al. Serum interlukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenisis. Ann Neurol. 1991;30:48-53.
• Heininger K, Liebert UG, Toyka KV, Haneveld FT, Schwendemann G, Kolb-Bachofen V, Ross HG, Cleveland S, Besinger UA, Gibbels E, et al: Chronic inflammatory polyneuropathy. Reduction of nerve conduction
  velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci. 1984 Oct;66(1):1-14.
• Hu W, Mathey E, Hartung HP, Kieseier BC. Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 2003;61:1774-1779.
• Kastenbauer S, Koedel U, Wick M, et al. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol. 2003;1137:210-217.
• Keifer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol. 2001;64:109-127.
• Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and MMP7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome. Ann Neurol. 1998;43:427-434.
• Kieseier BC, Dalakas MC, Hartung H-P. Inflammaotory mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002;59(Suppl 6)S7-S12.
• Köller H, Kieseier BC, Jander S, Hartung HP. Chronic Inflammatory Demylinating Polyneuropathy. N Engl J Med. 2005;352:1343-1356.
• Kwa MS, van Schaik IN, DeJonge RR, et al. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 2003;126:361-375.
• Leppert D, Hughes P, Huber S, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999;53:62-70.
• Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and Il-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci. 1999;163:47-52.
• Melendez-Vasquez C, Redford J, Choudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997;73:124-134.
• Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000;123(Pt 8):1660-1666.
• Previtali SC, Archelos JJ, Hartung HP. Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol. 1998;44:611-621.
• Previtali SC, Feltri ML, Archelos JJ, et al. Role of integrins in the peripheral nervous system. Prog Neurobiol. 2001;64:35-49.
• Quattrini A, Previtali SC, Kieseier BC, et al. Autoimmunity in the peripheral nervous system. Crit Rev Neurobiol. 2003;151:1-39.
• Rezania K, Gundogdu B, Soliven B. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Front Biosci. 2004;9:939-945.
• Van den Berg LH, Mollee I, Wokke JH, Logtenberg T. Increased frequencies of HRPT mutant T lymphocytes in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol. 1995;58:37-42.
• Van Rhijn I, Van den Berg LH, Bosboom WM, et al. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000;123:2020-2029.
• Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. et al. Neurology 1998;51(6):1738-1741.
• Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286-292.
• Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol. 2000;47:765-775.